Drug Profile
RO 6836191
Alternative Names: RO-6836191Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Roche
- Class Cardiovascular therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Atherosclerosis(In volunteers) in Netherlands (IV)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Atherosclerosis(In volunteers) in Netherlands (PO)
- 20 Nov 2013 Phase-I clinical trials in Atherosclerosis (in volunteers) in Netherlands (IV)